ERYTECH Pharma Stock Forecast, Price & News

ERYTECH Pharma (NASDAQ:ERYP) Frequently Asked Questions

Is ERYTECH Pharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ERYTECH Pharma in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ERYTECH Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ERYP, but not buy additional shares or sell existing shares.
View analyst ratings for ERYTECH Pharma or view top-rated stocks.

How has ERYTECH Pharma's stock price been impacted by Coronavirus?

ERYTECH Pharma's stock was trading at $5.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ERYP shares have decreased by 59.5% and is now trading at $2.12.
View which stocks have been most impacted by COVID-19.

Are investors shorting ERYTECH Pharma?

ERYTECH Pharma saw a increase in short interest during the month of December. As of December 15th, there was short interest totaling 206,400 shares, an increase of 1,395.7% from the November 30th total of 13,800 shares. Based on an average daily trading volume, of 168,300 shares, the short-interest ratio is currently 1.2 days.
View ERYTECH Pharma's Short Interest.

When is ERYTECH Pharma's next earnings date?

ERYTECH Pharma is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022.
View our earnings forecast for ERYTECH Pharma.

Who are ERYTECH Pharma's key executives?

ERYTECH Pharma's management team includes the following people:

• Gil Beyen, Chief Executive Officer & Director
• Eric Soyer, Chief Operating & Financial Officer
• Stewart Craig, Chief Technical Officer
• Iman El-Hariry, Chief Medical Officer
• Jérôme Bailly, Chief Quality Officer & Deputy General Manager

Who are some of ERYTECH Pharma's key competitors?

Some companies that are related to ERYTECH Pharma include Passage Bio (PASG), Environmental Impact Acquisition (ENVI), Compugen (CGEN), CEL-SCI (CVM), SAB Biotherapeutics (SABS), Compass Therapeutics (CMPX), Compass Therapeutics (CMPX), Genfit (GNFT), Acumen Pharmaceuticals (ABOS), SQZ Biotechnologies (SQZ), Gamida Cell (GMDA), Ambrx Biopharma (AMAM), Genenta Science (GNTA), Genenta Science (GNTA) and Candel Therapeutics (CADL).
View all of ERYP's competitors.

What other stocks do shareholders of ERYTECH Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ERYTECH Pharma investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Sesen Bio (SESN), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE), Gilead Sciences (GILD), MEI Pharma (MEIP), Verastem (VSTM) and ACADIA Pharmaceuticals (ACAD).

When did ERYTECH Pharma IPO?

(ERYP) raised $125 million in an initial public offering (IPO) on Friday, November 10th 2017. The company issued 5,300,000 shares at a price of $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF acted as the underwriters for the IPO and JMP Securities was co-manager.

What is ERYTECH Pharma's stock symbol?

ERYTECH Pharma trades on the NASDAQ under the ticker symbol "ERYP."

How do I buy shares of ERYTECH Pharma?

Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ERYTECH Pharma's stock price today?

One share of ERYP stock can currently be purchased for approximately $2.12.

How much money does ERYTECH Pharma make?

ERYTECH Pharma has a market capitalization of $65.76 million and generates $4.25 million in revenue each year.

How many employees does ERYTECH Pharma have?

ERYTECH Pharma employs 2,020 workers across the globe.

What is ERYTECH Pharma's official website?

The official website for ERYTECH Pharma is www.erytech.com.

Where are ERYTECH Pharma's headquarters?

ERYTECH Pharma is headquartered at 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008.

How can I contact ERYTECH Pharma?

ERYTECH Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at (347) 874-4438, via email at [email protected], or via fax at 33-4-78-75-56-29.